Janus kinase inhibitor

Janus kinase inhibitors, also known as JAK inhibitors, are a class of medications that modulate the activity of one or more of the Janus kinase (JAK) family of enzymes. These enzymes are crucial in the signaling pathways of cytokines and growth factors, which play essential roles in immune response, hematopoiesis, and various other cellular processes.

Mechanism of Action

JAK inhibitors target the Janus kinase enzymes, which are intracellular tyrosine kinases that mediate signaling for various cytokine receptors. The inhibition of these enzymes disrupts the JAK-STAT (signal transducer and activator of transcription) pathway, thereby modulating immune responses and inflammatory processes. The major JAK enzymes are:

• JAK1
• JAK2
• JAK3
• TYK2 (Tyrosine kinase 2)

JAK inhibitors selectively inhibit specific JAK isoforms, depending on the drug's design, and are often categorized based on their specificity.

Approved Indications

JAK inhibitors are used in the treatment of several autoimmune diseases, hematologic disorders, and other conditions. Common indications include:

• Rheumatoid arthritis (RA)
• Psoriatic arthritis (PsA)
• Ulcerative colitis (UC)
• Myelofibrosis (MF)
• Polycythemia vera (PV)
• Atopic dermatitis

Examples of JAK Inhibitors

Some widely used JAK inhibitors include:

• Tofacitinib - Primarily inhibits JAK1 and JAK3. Approved for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
• Baricitinib - Inhibits JAK1 and JAK2. Approved for rheumatoid arthritis and atopic dermatitis.
• Upadacitinib - Selective JAK1 inhibitor for rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis.
• Ruxolitinib - Targets JAK1 and JAK2. Used for myelofibrosis and polycythemia vera.
• Fedratinib - JAK2-selective inhibitor for the treatment of myelofibrosis.

Side Effects and Risks

The use of JAK inhibitors is associated with several potential side effects, some of which are serious:

• Increased risk of infection, including tuberculosis and opportunistic infections
• Elevated risk of thromboembolism and cardiovascular events
• Cytopenias, including neutropenia and anemia
• Potential for malignancies due to immunosuppression
• Gastrointestinal perforations (rare)

Close monitoring is recommended for patients on JAK inhibitors, particularly those with preexisting comorbidities.

Recent Advances

Ongoing research is exploring the role of JAK inhibitors in treating additional conditions such as COVID-19-related cytokine storms, alopecia areata, and certain forms of cancer. Studies are also underway to develop more selective JAK inhibitors with reduced side effects.

History

The discovery of JAK inhibitors was driven by the need for targeted therapies in autoimmune and inflammatory diseases. Tofacitinib was the first JAK inhibitor approved by the FDA in 2012 for rheumatoid arthritis. Subsequent approvals have expanded the therapeutic landscape.

See Also

• Signal transduction
• Immune checkpoint inhibitors
• Tyrosine kinase inhibitors
• Cytokine storm